Cargando…

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells

Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to evolve, with the development of genome analysis technology and the advent of molecular targeted drugs including tyrosine kinase inhibitors. Nevertheless, acquired drug resistance to molecular targete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshioka, Takahiro, Shien, Kazuhiko, Takeda, Tatsuaki, Takahashi, Yuta, Kurihara, Eisuke, Ogoshi, Yusuke, Namba, Kei, Torigoe, Hidejiro, Sato, Hiroki, Tomida, Shuta, Yamamoto, Hiromasa, Soh, Junichi, Fujiwara, Toshiyoshi, Toyooka, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676122/ https://www.ncbi.nlm.nih.gov/pubmed/31162771 http://dx.doi.org/10.1111/cas.14089

Ejemplares similares

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019)

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
por: Namba, Kei, et al.
Publicado: (2019)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis
por: Takahashi, Yuta, et al.
Publicado: (2018)

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018)

YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers
por: Takeda, Tatsuaki, et al.
Publicado: (2020)

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
por: Sato, Hiroki, et al.
Publicado: (2018)

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer
por: Takeda, Tatsuaki, et al.
Publicado: (2017)

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
por: Ohtsuka, Tomoaki, et al.
Publicado: (2016)

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
por: Sato, Hiroki, et al.
Publicado: (2017)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

DV200 Index for Assessing RNA Integrity in Next-Generation Sequencing
por: Matsubara, Takehiro, et al.
Publicado: (2020)

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
por: Hashida, Shinsuke, et al.
Publicado: (2015)

One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective study
por: Namba, Kei, et al.
Publicado: (2022)

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast
por: Ochi, Kosuke, et al.
Publicado: (2022)

ASO Author Reflections: Prognostic Impact of the Primary Tumor Resection for Lung Cancer Patients Diagnosed with Pleural Dissemination in the Perioperative Period—Importance of Biomarker-Based Treatment Decision Making
por: Shien, Kazuhiko, et al.
Publicado: (2023)

Identification of genetic loci associated with renal dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
por: Tomioka, Yasuaki, et al.
Publicado: (2023)

Author Correction: Identification of genetic loci associated with renal dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
por: Tomioka, Yasuaki, et al.
Publicado: (2023)

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
por: Yamamoto, Hiromasa, et al.
Publicado: (2013)

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
por: Ikeda, Hirokuni, et al.
Publicado: (2010)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Induction Chemoradiotherapy Followed by Surgical Resection for Clinical T3 or T4 Locally Advanced Non–Small Cell Lung Cancer
por: Shien, Kazuhiko, et al.
Publicado: (2012)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Primary pulmonary melanoma: a report of two cases
por: Watanabe, Mototsugu, et al.
Publicado: (2015)

EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
por: Fujiwara, Toshiya, et al.
Publicado: (2023)

Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer
por: Shien, Kazuhiko, et al.
Publicado: (2014)

Robot-assisted thoracoscopic lobectomy for severe incomplete interlober fissure
por: Okazaki, Mikio, et al.
Publicado: (2021)

Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness
por: Chen, Youyi, et al.
Publicado: (2019)

Robotic Mediastinal Tumor Resections: Position and Port Placement
por: Okazaki, Mikio, et al.
Publicado: (2022)

A Case of Carcinoma Showing Thymus-Like Differentiation with a Rapidly Lethal Course
por: Nogami, Tomohiro, et al.
Publicado: (2014)

Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
por: Okumura, Norihito, et al.
Publicado: (2021)

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
por: Tomioka, Yasuaki, et al.
Publicado: (2021)

The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells
por: MAKI, YUHO, et al.
Publicado: (2016)

β-1,3-Galactosyl-O-Glycosyl-Glycoprotein β-1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility
por: Sumardika, I Wayan, et al.
Publicado: (2018)

An EGFR-Amplified Cervical Squamous Cell Carcinoma Patient with Pulmonary Metastasis Benefits from Afatinib: A Case Report
por: Chen, Qian, et al.
Publicado: (2020)

High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
por: Takahashi, Takayuki, et al.
Publicado: (2021)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Successful wound treatment using negative pressure wound therapy without primary closure in a patient undergoing highly contaminated abdominal surgery
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
por: Harada, Yohei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_84q601v799flkuo1oqg79lpj36